IOL Chem & Pharma
Ticker > Company >

IOL Chem & Pharma share price

IOL Chemicals And Pharmaceuticals Ltd.

NSE: IOLCP BSE: 524164 SECTOR: Pharmaceuticals & Drugs  2.2 L   2.31 K   316

91.68
-0.79 (-0.85%)
BSE: 18 Jul 04:01 PM

Price Summary

Today's High

₹ 94.19

Today's Low

₹ 90.97

52 Week High

₹ 107.41

52 Week Low

₹ 57.51

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 2691.06 Cr.

Enterprise Value

₹ 2581.2 Cr.

No. of Shares

29.35 Cr.

P/E

26.64

P/B

1.59

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  57.49

CASH

₹ 142.62 Cr.

DEBT

₹ 32.76 Cr.

Promoter Holding

52.62 %

EPS (TTM)

₹  3.44

Sales Growth

-3.8%

ROE

8.69 %

ROCE

12.3%

Profit Growth

-3.26 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-3.8%
3 Year2.73%
5 Year4.82%

Profit Growth

1 Year-3.26%
3 Year-32.72%
5 Year-10.57%

ROE%

1 Year8.69%
3 Year10.28%
5 Year26.17%

ROCE %

1 Year12.3%
3 Year14.37%
5 Year33.08%

Debt/Equity

0.0203

Price to Cash Flow

9.26

Interest Cover Ratio

12.3441

CFO/PAT (5 Yr. Avg.)

1.08710331940557

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 52.62 0.00
Dec 2024 52.62 0.00
Sep 2024 48.19 0.00
Jun 2024 48.19 0.00
Mar 2024 48.19 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 46.87 Cr.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 12.3441.
  • The company has an efficient Cash Conversion Cycle of 45.4212 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.08710331940557.
  • The company has a high promoter holding of 52.62%.

 Limitations

  • The company has shown a poor profit growth of -32.7151210799305% for the Past 3 years.
  • The company has shown a poor revenue growth of 2.73441053792856% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 503.92 502.38 525.75 523.3 527.78
Total Expenditure 453.84 451.58 484.19 476.43 464.84
Operating Profit 50.08 50.8 41.56 46.87 62.94
Other Income 7.52 7.38 6.43 4.07 4.52
Interest 3.41 2.15 4.12 4.46 4.03
Depreciation 16.42 16.8 17.93 18.66 18.53
Exceptional Items 0 0 0 0 0
Profit Before Tax 37.77 39.23 25.94 27.82 44.9
Tax 9.58 9.55 6.79 7.27 13.28
Profit After Tax 28.19 29.68 19.15 20.55 31.62
Adjusted EPS (Rs) 0.96 1.01 0.65 0.7 1.08

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 1894.47 1966.98 2184.02 2217.11 2132.79
Total Expenditure 1320.59 1375.14 1927.74 1990.59 1901.27
Operating Profit 573.88 591.84 256.28 226.52 231.52
Other Income 16.02 24.3 32.04 25.57 30.07
Interest 20.93 5.83 8.29 16.47 16.1
Depreciation 35.73 38.92 43.26 46.13 62.85
Exceptional Items 0 0 -13.93 0 0
Profit Before Tax 533.24 571.39 222.84 189.49 182.64
Tax 171.95 126.83 57.18 49.51 47.22
Net Profit 361.29 444.56 165.66 139.98 135.42
Adjusted EPS (Rs.) 12.7 15.14 5.64 4.77 4.61

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 56.89 58.71 58.71 58.71 58.71
Total Reserves 756.65 1201.72 1331.56 1447.84 1552.62
Borrowings 0 0 0 0 0
Other N/C liabilities 79.73 59.11 56.62 58.15 72.89
Current liabilities 453.63 432.8 575.29 502.17 596.85
Total Liabilities 1346.9 1752.34 2022.18 2066.87 2281.07
Assets
Net Block 469.04 512.36 560.64 751.31 932.69
Capital WIP 19.19 48.27 102.03 81.4 99.83
Intangible WIP 0 0 3.17 8.24 1.04
Investments 0 0 0.1 17.71 17.71
Loans & Advances 1.33 17.61 10.77 9.52 23.62
Other N/C Assets 9.43 21.95 204.87 233.36 49.6
Current Assets 847.91 1152.15 1140.6 965.33 1156.58
Total Assets 1346.9 1752.34 2022.18 2066.87 2281.07
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 533.24 571.39 222.84 189.49 182.64
Adjustment 51.93 27.15 33.12 44.42 60.06
Changes in Assets & Liabilities 2.78 -76.51 -102.34 -63.67 90.08
Tax Paid -117.15 -142.25 -62.58 -47.1 -42.02
Operating Cash Flow 470.8 379.78 91.04 123.14 290.76
Investing Cash Flow -184.23 -317.25 -120.62 -119.19 -191.69
Financing Cash Flow -271.89 -58.28 -1.64 -4.11 -92.5
Net Cash Flow 14.68 4.25 -31.22 -0.16 6.57

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 48.19 48.19 48.19 52.62 52.62
maya devi polycot limited... 21.54 21.54 21.54 21.54 21.54
ncvi enterprises limited 15.96 15.96 15.96 15.96 15.96
nm merchantiles private l... - - - - 13.08
varinder gupta 2.04 2.04 2.04 2.04 2.04
nm merchantiles pvt limit... 8.65 8.65 8.65 13.08 -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 51.81 51.81 51.81 47.38 47.38
g consultants and fabrica... - - - - 1.68
llp - - 0.32 0.36 0.25
vasudeva commercials limi... 7.94 7.94 7.94 7.94 7.94
g consultants and fabrica... 1.68 1.68 1.68 1.68 -
enorg limited 4.43 4.43 4.43 - -

Annual Reports

Title Link
Title Link
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
Credit CARE
Credit CARE
Credit CARE
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
Research HDFC Securities
Research Nuvama

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY25
Concall Q4FY24
Concall Q3FY25
Concall Q3FY24
Concall Q3FY22
Concall Q3FY21
Concall Q2FY25
Concall Q2FY24
Concall Q2FY21
Concall Q1FY25
Concall Q1FY24
Concall Q1FY23
Concall Q1FY22
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY22
Presentation Q4FY21
Presentation Q3FY24
Presentation Q3FY22
Presentation Q3FY21
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY22

Company News

IOL Chemicals registers Acetic Anhydride with REACH 16 Jun, 12:30 PM IOL Chemicals & Pharmaceuticals informs about outcome of board meeting 17 May, 2:29 PM IOL Chem & Pharma - Quaterly Results 16 May, 7:06 PM IOL Chem & Pharma - Quaterly Results 16 May, 7:06 PM IOL Chemicals secures approval for Ibuprofen from CDE in China 29 Apr, 12:12 PM IOL Chemicals & Pharmaceuticals informs about trading window closure 26 Mar, 11:20 AM IOL Chemicals commences new Unit 11 for Paracetamol production in Punjab 25 Mar, 11:09 AM IOL Chemicals and Pharmaceuticals gets Certificate of Suitability from EDQM 6 Mar, 2:19 PM IOL Chemicals and Pharmaceuticals reports 11% fall in Q3 consolidated net profit 13 Feb, 3:28 PM IOL Chem & Pharma - Quaterly Results 12 Feb, 6:05 PM IOL Chem & Pharma - Quaterly Results 12 Feb, 6:05 PM IOL Chemicals & Pharmaceuticals informs about newspaper publication 2 Jan, 4:48 PM IOL Chemicals & Pharmaceuticals informs about disclosures 26 Nov, 5:24 PM IOL Chemicals and Pharmaceuticals informs about issuance letter of confirmation 21 Nov, 5:06 PM IOL Chem & Pharma - Quaterly Results 14 Nov, 5:00 PM IOL Chemicals and Pharmaceuticals informs about outcome of board meeting 28 Oct, 2:30 PM IOL Chemicals & Pharmaceuticals informs about details of loss of certificate 5 Oct, 11:51 AM IOL Chemicals and Pharmaceuticals reports 35% fall in Q1 consolidated net profit 12 Aug, 12:00 PM IOL Chem & Pharma - Quaterly Results 9 Aug, 6:37 PM IOL Chem & Pharma - Quaterly Results 9 Aug, 6:37 PM IOL Chemicals gets certificate of suitability from EDQM for Valsartan 24 Jul, 11:00 AM IOL Chemicals gets nod to export ‘Fenofibrate API’ in China market 2 Jul, 10:49 AM Iol Chemicals & Pharmaceuticals informs about press release 18 Jun, 2:52 PM IOL Chemicals & Pharmaceuticals informs about schedule of analyst meeting 15 Jun, 3:41 PM IOL Chemicals gets certificate of suitability for ‘Pantoprazole Sodium Sesquihydrate’ 12 Jun, 11:41 AM IOL Chemicals gets CEP certificate for Allopurinol from EDQM 12 Jun, 10:59 AM Iol Chemicals & Pharmaceuticals informs about loss of share certificates 5 Jun, 5:27 PM IOL Chemicals & Pharmaceuticals informs about loss of share certificate 24 May, 11:55 AM IOL Chemicals and Pharmaceuticals informs about loss of share certificate 18 May, 12:41 PM IOL Chem & Pharma - Quaterly Results 14 May, 4:59 PM IOL Chem & Pharma - Quaterly Results 14 May, 4:59 PM IOL Chem & Pharma - Quaterly Results 14 May, 4:59 PM Iol Chemicals & Pharmaceuticals informs about GMP certificate 3 May, 5:12 PM IOL Chemicals and Pharmaceuticals informs about loss of share certificate 24 Apr, 5:33 PM IOL Chemicals completes ANVISA GMP audit of 10 manufacturing units without any observation 19 Mar, 12:30 PM IOL Chemicals gets approval for ‘Metformin Hydrochloride’ from CDE in China 19 Feb, 3:37 PM IOL Chemicals gets nod to wind up ‘M/s IOL Global’ in UK 7 Feb, 3:30 PM IOL Chemicals and Pharmaceuticals reports marginal fall in Q3 consolidated net profit 7 Feb, 2:24 PM IOL Chem & Pharma - Quaterly Results 6 Feb, 6:15 PM IOL Chem & Pharma - Quaterly Results 6 Feb, 6:15 PM IOL Chem & Pharma - Quaterly Results 6 Feb, 6:15 PM Iol Chemicals & Pharmaceuticals informs about analyst meet 13 Dec, 2:36 PM IOL Chem & Pharma - Quaterly Results 8 Nov, 4:06 PM IOL Chem & Pharma - Quaterly Results 8 Nov, 4:06 PM IOL Chem & Pharma - Quaterly Results 8 Nov, 4:06 PM IOL Chemicals and Pharmaceuticals informs about disclosure 28 Sep, 10:16 AM IOL Chemicals and Pharmaceuticals informs about disclosure 28 Sep, 10:16 AM IOL Chem & Pharma - Quaterly Results 9 Aug, 6:05 PM IOL Chem & Pharma - Quaterly Results 9 Aug, 6:05 PM IOL Chemicals & Pharmaceuticals informs about details of loss of certificate 25 Jul, 4:04 PM

IOL Chem & Pharma Stock Price Analysis and Quick Research Report. Is IOL Chem & Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into IOL Chem & Pharma and its performance over the period of time. IOL Chem & Pharma stock price today is Rs 91.8.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. IOL Chem & Pharma cash from the operating activity was Rs 290.76 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. IOL Chem & Pharma has a Debt to Equity ratio of 0.0203 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In IOL Chem & Pharma , the EPS growth was -3.2576 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, IOL Chem & Pharma has OPM of 10.8552647002283 % which is a bad sign for profitability.
     
  • ROE: IOL Chem & Pharma have a poor ROE of 8.6867 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of IOL Chem & Pharma is Rs 91.8. One can use valuation calculators of ticker to know if IOL Chem & Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about IOL Chem & Pharma

IOL Chemicals And Pharmaceuticals Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

IOL Chemicals And Pharmaceuticals Ltd. is a renowned pharmaceutical company that specializes in manufacturing bulk drugs, specialty chemicals, and intermediates. With a strong focus on research and development, IOL Chemicals has established a reputation for producing high-quality products that meet international standards. The company's commitment to innovation and customer satisfaction has positioned it as a trusted partner for various healthcare and pharmaceutical organizations around the globe.

IOL Chemicals And Pharmaceuticals Ltd. - Share Price

The share price of IOL Chemicals And Pharmaceuticals Ltd. is an important aspect of the company's stock analysis. It reflects the market's perception of the company's performance, growth potential, and overall value. Investors can find the latest share price of IOL Chemicals on our website, along with historical data and interactive price charts to help analyze trends and patterns over time.

IOL Chemicals And Pharmaceuticals Ltd. - Balance Sheet

Analyzing the balance sheet of IOL Chemicals And Pharmaceuticals Ltd. provides essential insights into the company's financial health and stability. Our pre-built screening tools allow long-term stock investors to assess the company's assets, liabilities, and equity in a structured manner. For a more in-depth analysis, our premium features enable fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

IOL Chemicals And Pharmaceuticals Ltd. - Annual Report

The annual report of IOL Chemicals And Pharmaceuticals Ltd. serves as a comprehensive overview of the company's performance, achievements, and future prospects. Our website provides downloadable copies of the company's annual reports, enabling investors to delve deeper into the financial statements, management's discussions and analysis, and other significant information essential for stock analysis.

IOL Chemicals And Pharmaceuticals Ltd. - Dividend

For investors seeking regular income from their investments, dividends play a crucial role in stock analysis. IOL Chemicals And Pharmaceuticals Ltd. has a track record of rewarding its shareholders with consistent dividend payouts. Our website provides information on the company's dividend history, payout ratio, and dividend yield, aiding investors in assessing the potential returns they may receive through dividend income.

IOL Chemicals And Pharmaceuticals Ltd. - Quarterly Result

Staying updated with the latest quarterly results is vital in stock analysis, as it allows investors to evaluate a company's financial performance and identify any emerging trends or concerns. Our website offers access to IOL Chemicals And Pharmaceuticals Ltd.'s quarterly results, including key financial indicators, revenue growth, profit margins, and other relevant metrics. This information can be combined with our premium features to facilitate fair value calculations.

IOL Chemicals And Pharmaceuticals Ltd. - Stock Price

Monitoring the stock price of IOL Chemicals And Pharmaceuticals Ltd. is crucial for investors to make informed decisions. Our website provides real-time and historical stock prices along with interactive price charts to help analyze market trends. Investors can also utilize our pre-built screening tools to filter stocks based on specific criteria and compare the performance of IOL Chemicals with its peers.

IOL Chemicals And Pharmaceuticals Ltd. - Price Chart

The price chart of IOL Chemicals And Pharmaceuticals Ltd. visualizes the historical movement of the stock price over time. By examining the price chart, investors can identify patterns, trends, and support-resistance levels, aiding in technical analysis. Our website provides interactive price charts with various customization options, allowing investors to analyze and interpret the stock price movements in the desired time frame.

IOL Chemicals And Pharmaceuticals Ltd. - News

Staying updated with the latest news and developments related to IOL Chemicals And Pharmaceuticals Ltd. is crucial for stock analysis. Our website offers a dedicated section for company news, where investors can find the latest announcements, press releases, regulatory updates, and other relevant information. This comprehensive news coverage ensures that investors stay well-informed and make data-driven decisions.

IOL Chemicals And Pharmaceuticals Ltd. - Concall Transcripts

Concall transcripts provide valuable insights into the discussions and strategies shared during the company's conference calls with analysts and investors. Our website provides downloadable concall transcripts of IOL Chemicals And Pharmaceuticals Ltd., enabling investors to gain a deeper understanding of the company's outlook, growth plans, and response to market dynamics. These transcripts are essential for long-term stock investors seeking a comprehensive stock analysis.

IOL Chemicals And Pharmaceuticals Ltd. - Investor Presentations

Investor presentations serve as a valuable resource for understanding a company's performance, growth strategies, and future prospects. Our website offers downloadable investor presentations of IOL Chemicals And Pharmaceuticals Ltd., providing investors with detailed insights into the company's business model, financial performance, and market positioning. These presentations are a valuable tool for stock analysis, helping investors make informed investment decisions.

IOL Chemicals And Pharmaceuticals Ltd. - Promoters

Promoters play a significant role in influencing a company's direction, decisions, and growth. IOL Chemicals And Pharmaceuticals Ltd. boasts a dedicated and experienced group of promoters who have been instrumental in shaping the company's success. Our website provides comprehensive information about the promoters of IOL Chemicals, including their background, expertise, and significant contributions to the company's growth story.

IOL Chemicals And Pharmaceuticals Ltd. - Shareholders

Understanding the ownership structure and major shareholders of a company is vital for stock analysis. Our website provides information on the major shareholders of IOL Chemicals And Pharmaceuticals Ltd., helping investors gauge the level of institutional interest and the distribution of ownership. Such insights enable investors to assess the confidence that other market participants have in the company and make informed investment decisions.

Please note that our website offers additional premium features, including fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. Additionally, we provide various pre-built screening tools that help investors filter stocks based on specific criteria for a more focused stock analysis.

 (Note: This content is tailored specifically for a website and does not contain any financial data points, numbers, or a conclusion.)  

IOL Chemicals And Pharmaceuticals Reserves

Over the past four years, IOL Chemicals And Pharmaceuticals Ltd has consistently increased its reserves, from Rs. 756.65 Cr in March 2020 to a substantial Rs. 1,552.62 Cr by March 2024. This growth represents the company's robust retention of earnings and hints at a strong underlying business model.

IOL Chemicals And Pharmaceuticals Balance Sheet

Analyzing the balance sheet of IOL Chemicals And Pharmaceuticals reveals a debt-free status for the company from March 2020 through to March 2024. With total liabilities climbing from Rs. 1,346.90 Cr in March 2020 to Rs. 2,281.07 Cr in March 2024, the company has managed its financial obligations without resorting to borrowing, indicating prudent financial management.

IOL Chemicals And Pharmaceuticals Assets

The total assets of IOL Chemicals And Pharmaceuticals have shown a steady increase, mirroring the rise in liabilities, and have maintained balance sheet parity over the years. The company's assets grew from Rs. 1,346.90 Cr in March 2020 to Rs. 2,281.07 Cr in March 2024, with a significant enhancement in net block, from Rs. 469.04 Cr to Rs. 932.69 Cr, pointing towards substantial capital investments.

IOL Chemicals And Pharmaceuticals Current Liabilities

Current liabilities of IOL Chemicals And Pharmaceuticals have seen fluctuations with an increase from Rs. 453.63 Cr in March 2020 to Rs. 596.85 Cr in March 2024. This may reflect the company's expansion in operations or changes in working capital requirements.

The data presented here is an analysis of the standalone balance sheet of IOL Chemicals And Pharmaceuticals. It serves as a critical tool for investors screening for financially stable companies in the market, providing insights alongside other factors like NSE/BSE indices, sector trends, and upcoming IPOs.

Read More
X